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Background: Over-reliance on opioids in
the perioperative period has contributed to
the opioid epidemic and new non-opioid
strategies for multi-modal analgesia are
being analyzed and implemented with
anesthesiologists playing a vital role. Data
regarding the pattern of opioid use intraoperatively is scarce. This study evaluates
the trend of intraoperative opioid analgesic
use at our institution from 2014 to 2018
among patients undergoing laparoscopic
cholecystectomy.

Methods: We analyzed a retrospective cohort
of 2,554 patients without opioid dependence,
liver, or renal failure who were administered
opioids intraoperatively. Doses of each opioid
were converted into morphine milligram
equivalents (MMEs). Data were analyzed via
univariate and multivariate linear regression
models including surgery date, age, BMI,
length of surgery, gender, race, and procedure.
Results: Fentanyl was the most commonly
prescribed opioid medication intraoperatively,
and it was typically prescribed alone. There
was a continuous decrease in intraoperative
MMEs from 2014 to 2018. Sub-analyses
among patients who were prescribed fentanyl
alone or fentanyl and hydromorphone
together indicated that the use of fentanyl

and hydromorphone decreased concurrently
during the study period.
Conclusions: Our study shows a trend
of decreasing opioid administration
 
      
linked to the opioid epidemic and efforts
to control opioid administration. However,
this study reports isolated trends in opioid
administration during the intraoperative
period and does not quantify other analgesic
modality utilization. Further studies
comparing intra-operative opioid and nonopioid analgesic use, and related patients’ pain
           
of alternative methods. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.014
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Background: To evaluate the role of
accelerated fractionated salvage radiation
therapy (SRT) in patients with diffuse large
B-cell lymphoma (DLBCL) refractory to
salvage chemotherapy in preparation for high
dose chemotherapy (HDT) and autologous
stem cell transplant (ASCT). Relapsed/
primary refractory patients who are also
salvage chemotherapy refractory are usually
not considered eligible for HDT and ASCT.
Conventional and accelerated fractionated
salvage radiation therapy was used with
the goal of making salvage chemotherapy
refractory patients eligible for HDT and
ASCT. Patients receiving two different
radiation therapy fractionation schedules were
compared.
Methods: We reviewed the medical records
of 54 consecutive patients at one institution
with DLBCL who were refractory to salvage
chemotherapy and underwent salvage
radiation therapy (SRT) from 2000-2019.
       
fractionated SRT (most commonly 3600 cGy
in 20 twice daily 180 cGy fractions) and 19
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patients underwent conventional fractionated
SRT (most commonly 3600 cGy in 20 daily
180 cGy fractions). Patients were excluded
if they had a complete response to salvage
chemotherapy or the SRT fraction size <150
cGy.
Results: We evaluated 35 males (65%) and
19 females (35%) with a median age of 59
(range: 24-81) at the time of SRT. Thirty
patients (56%) had primary chemotherapy
refractory DLBCL having never achieved a
remission and were also refractory to salvage
chemotherapy, while 24 patients (44%)
were refractory to salvage chemotherapy
following relapse. All patients were found
to have progressive disease in response to
salvage chemotherapy. Thirty-seven patients
(69%) underwent high dose chemotherapy
and proceeded to HDT and ASCT within
180 days of radiation therapy. Accelerated
fractionation compared to conventional
 
improvement in complete response (CR) rate
(80% vs 26%, p<0.001), 1-year disease free
survival (54% vs 26%, p<0.001), and 1-year
overall survival (61% vs 39%, p=0.018).
The rate of patients undergoing ASCT was
    

undergoing accelerated fractionation (73% vs
60%, p=0.14).
Conclusion: In patients with DLBCL who are
refractory to salvage chemotherapy, the use
of salvage radiation therapy was associated
with a high rate of conversion to ASCT
eligibility in a group of patients that are
frequently ineligible for ASCT. Additionally,
the use of accelerated fractionation compared
to conventional fractionation SRT was
   
rate, PFS, and OS. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.015
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